Continuously relapsing (for two years) course of diarrheal variant of IBS (Clinical case)

The aim of the publication. By the example of clinical case to show modern algorithm of diagnostics and choice of pathogenically proved treatment for patient with continuously relapsing course of irritable bowel syndrome (IBS).

Key points. Patient S., 20 years, has addressed in clinic with symptoms of boring pain in the lower regions of the abdomen, aggravating after meal and decreasing after defecation, increase of stool frequency up to 6 times day, mainly in the morning time, general weakness. Symptoms developed about two years ago after the intake of unsound food nausea, vomiting by taken food, abdominal pain, frequent stool with admixture of mucus appeared. Patient had no nausea and vomiting the next day, however the abdominal pain and unstable stool persisted for a long time. The patient was repeatedly examined, but according to carried out investigation no significant changes were revealed. Antispasmodics of various groups, enzyme and antisecretory agents in this relation were prescribed to him without any noteworthy effect for two years prior to admission to Vasilenko Clinic of internal diseases propedeutics, gastroenterology and hepatology. In the clinic differential diagnosis between organic diseases of gastro-intestinal tract was carried out (erosive-ulcerative lesion of the upper parts of GIT, celiac disease, inflammatory bowel diseases), functional gastro-intestinal disorder, thyroid gland hyperfunction). According to symptoms, data of past history and carried out investigation clinical diagnosis was made: postinfectious irritable bowel syndrome, diarrhea-prevalent variant. Prescribed treatment included dioctaedric smectite, probiotic and antipsychotic drug, which had led to complete relief of all symptoms.

Conclusion. Careful taking past history and carrying out detailed laboratory and instrumental tool investigation allowed to establish clinical diagnosis in the patient, and pathogenicly proven treatment promoted achievement of disease remission.

1. Адлер Г. Болезнь Крона и язвенный колит: Перевод А.А. Шептулина. – М: ГЭОТАР-Медиа, 2000. – 500 с.

2. Ивашкин В.Т., Полуэктова Е.А. Функциональные расстройства желудочно-кишечного тракта. – М.: Медпресс-информ, 2013.

3. Ивашкин В.Т., Шептулин А.А., Склянская О.А. Синдром диареи. – М: ГЭОТАР-Медиа, 2002.

4. Крыжановский Г.Н. Дизрегуляционная патология: Руководство для врачей и биологов. – М.: Медицина, 2002.

5. Курбатова А.А. Патогенетическое и клиническое значение системы цитокинов и клаудинов у больных с синдромом раздраженного кишечника: Дис. … канд. мед. наук. – М., 2013.

6. Новиков А.В., Яхно Н.Н. Невропатическая боль, патофизиологические механизмы и принципы терапии // Рус. мед. журн. – 2001. – № 9 (7–8). – С. 318–327.

7. Полуэктова Е.А. Некоторые особенности патогенеза, клиники, диагностики и лечения синдрома раздраженного кишечника: Дис. … канд. мед. наук. – М., 2002.

8. Полуэктова Е.А., Кучумова С.Ю., Шептулин А.А., Ивашкин В.Т. Лечение синдрома раздраженного кишечника с позиций современных представлений о патогенезе заболевания // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2013. – Т. 23, № 1. – С. 57–65.

9. Щербаков П.Л., Петухов В.А. Сравнительная эффективность энтеросорбентов при диарее у детей // Вопр. современной педиатрии. – 2005. – Т. 4, № 4. – С. 85–89.

10. Юрманова Е.Н. Отдаленные результаты лечения и прогноз пациентов с синдромом раздраженного кишечника: Дис. … канд. мед. наук. – М., 2007.

11. Belmonte L., Beutheu-Youmba S., Bertiaux-Vandaële N. et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype // PLoS. One. – 2012. – Vol. 7 (8).

12. Chang F.Y., Lu C.L., Chen C.Y., Luo J.C. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome // J. Gastroenterol. Hepatol. – 2007. – Vol. 22 (12). – P. 2266–2272.

13. Clarke G., Cryan J.F., Dinan T.G., Quigley E.M. Review article: probiotics for the treatment of irritable bowel syndrome – focus on lactic acid bacteria // Aliment. Pharmacol. Ther. – 2012. – Vol. 35. – P. 403–413.

14. Devor M. Pain mechanism and pain syndromes // IASP Press. – 1996. – P. 103–112.

15. Dlugosz A., Lindberg G. The expression of toll-like receptor 4 in colon mucosa is as up-regulated in irritable bowel syndrome as it is in inflammatory bowel disease // Gut. – 2010. – Vol. 59 (suppl. II). – P. 31.

16. Drossman D.A. Rome III: the new criteria // Chin. J. Dig. Dis. – 2006. – Vol. 7 (4). – P. 181–185.

17. Floch M.H., Walker W.A., Madsen K. et al. Recommendations for probiotic use-2011 update // J. Clin. Gastroenterol. – 2011. – Vol. 45. – Р. 168–71.

18. Ford A.C., Talley N.J., Schoenfeld P.S. et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis // Gut. – 2009. – Vol. 58. – P. 367–378.

19. Ford A.C., Talley N.J., Schoenfeld P.S. et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review // Gut. – 2009. – Vol. 58 (3). – P. 367–378.

20. Khan M.W., Kale A.A., Bere P. et al. Microbes, intestinal inflammation and probiotics // Expert Rev. Gastroenterol. Hepatol. – 2012. – Vol. 6. – P. 81–94.

21. Kong W.M., Gong J., Dong L., Xu J.R. Changes of tight junction claudin-1,-3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome // Nan Fang Yi Ke Da Xue Xue Bao. – 2007. – Vol. 27. – P. 1345–1347.

22. Locke G.R., Zinsmeister A.R., Talley N.J. et al. Familial association in adults with functional gastrointestinal disorders // Mayo Clin. Proc. – 2000. – Vol. 75. – P. 907–912.

23. Macsharry J., O’Mahony L., Fanning A. et al. Mucosal cytokine imbalance in irritable bowel syndrome // Scand. J. Gastroenterol. – 2008. – Vol. 12. – Р. 1467–1476.

24. Mahraoui L., Heyman M. et al. Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha // Gut. – 1997. – Vol. 40. P. 339–343.

25. Pimentel M., Chow E.J., Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome // Am. J. Gastroenterol. – 2000. – Vol. 95. – Р. 3503–3506.

26. Pimentel M., Chow E.J., Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study // Am. J. Gastroenterol. – 2003. – Vol. 98. – Р. 412–419.

27. Ponnusamy K. et al. Microbial community and metabolomic comparison of irritable bowel syndrome faeces // J. Med. Microbiol. – 2011. – Vol. 60. – Р. 817–827.

28. Rateau J.G., Morgant G., Droy-Priot M.T., Parier J.L. A histological, enzymatic and water-electrolyte study of the action of smectite, a mucoprotective clay, on experimental infectious diarrhoea in the rabbit // Curr. Med. Res. Opin. – 1982. – Vol. 8. – P. 233–241.

29. Turco F., Cirillo C. et al. Human derived enteroglial cells express toll-like receptors MRNA and respond to pathogen and probiotic bacteria // Gut. – 2010. – Vol. 59 (suppl. II). – P. A51.

30. Turksen K., Troy T.C. Barriers built on claudins // J. Cell Sci. – 2004. – Vol. 117. – P. 2435–2447.